Interleukin Genetics and Alticor Agree on Expansion of Distribution Channels for Genetic Tests

Interleukin Genetics, Inc. (Waltham, MA, USA), and Access Business Group International LLC (Ada, MI, USA), a division of Alticor Inc., have reached an agreement that will increase access to all intellectual property related to genetic tests jointly developed by Interleukin Genetics and Access Business Group under their research agreements.

In turn, this will permit the expansion of Interleukin Genetics' distribution network for such genetic tests. Under the agreement, Access Business Group's existing license to the Interleukin Genetics' intellectual property will become non-exclusive.

Interleukin Genetics will have the right to brand, market, sell, and distribute all genetic tests developed using its existing and future intellectual property, either itself or through additional third-party licensees. Access Business Group will continue to distribute the Heart Health and General Nutrition genetic tests under the Gensona brand name.

The agreement will continue to allow Interleukin Genetics to have exclusive ownership of all inventions relating to genetic tests arising from research programs between the companies. Lewis H. Bender, chief executive officer at Interleukin Genetics, commented, "This is an excellent agreement for Interleukin Genetics as we now have the opportunity to aggressively pursue new partnerships for distribution of the genetic tests and intellectual property created over the years with our partner, Access Business Group. We are excited to continue our current efforts to out-license our intellectual property to companies in the biotechnology, molecular diagnostic, pharmaceutical, direct sales, and consumer products areas.”

Interleukin Genetics is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics currently offers an array of Nutraceuticals and OTCeuticals, including Ginkoba, Ginsana, and Venastat, which are sold at the US's largest food, drug, and mass retailers, and has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment.

Related Links:
Interleukin Genetics
Access Business Group International